Bat-specific adaptations in interferon signaling and GBP1 contribute to enhanced antiviral capacity.

Publication date: Jul 01, 2025

Bats are reservoirs of emerging zoonotic viruses that may cause severe disease in humans and agricultural animals. However, it is poorly understood how bats can tolerate diverse viral infections. Here, we characterized type I interferon response pathways in kidney cell lines derived from two divergent bat species, Pteropus alecto and Eptesicus fuscus, identifying distinct mechanisms underlying their enhanced control of viral infection. We demonstrate the critical roles of STAT1/STAT2 in IFNβ signaling, along with species-specific adaptations that contribute towards a steady and ready antiviral state. Unlike in humans, bat IFNβ signaling processes resist the immune antagonistic properties of MERS-CoV which further explains the ability of bats to tolerate coronavirus infections. Transcriptomic analysis on interferon stimulated cell lines identified canonical and non-canonical interferon stimulated genes including two differentially expressed genes, IFIT1 and GBP1, that exhibit enhanced antiviral activity against a wide range of viruses, including the bat-derived Eptesipoxvirus. We have identified a functional (AV1) motif within E. fuscus GBP1 that restricts Eptesipoxvirus replication. Ultimately, our work provides important insights into the evolution of enhanced interferon-mediated antiviral responses in bats, contributing to their ability to resist viral diseases.

Open Access PDF

Concepts Keywords
Agricultural Adaptation, Physiological
Bats Animals
Eptesipoxvirus Antigens, Differentiation
Kidney Antigens, Differentiation
Zoonotic Antiviral Agents
Antiviral Agents
Cell Line
Chiroptera
Humans
Interferon-beta
Interferon-beta
Interferons
Interferons
leu-13 antigen
Signal Transduction
Species Specificity
STAT1 Transcription Factor
STAT1 Transcription Factor
STAT2 Transcription Factor
STAT2 Transcription Factor

Semantics

Type Source Name
pathway REACTOME Interferon Signaling
disease MESH viral infections
disease IDO cell
disease MESH coronavirus infections
disease IDO replication
drug DRUGBANK Citalopram
drug DRUGBANK Esomeprazole
disease MESH infections
disease IDO infection
disease IDO host
pathway REACTOME Innate Immune System
disease MESH PRRs
disease IDO pathogen
disease IDO nucleic acid
disease IDO assay
disease MESH viral load
drug DRUGBANK L-Tyrosine
drug DRUGBANK Staurosporine
pathway REACTOME Translation
drug DRUGBANK Trestolone
disease IDO innate immune response
disease IDO process
drug DRUGBANK Coenzyme M
pathway REACTOME Signal Transduction

Original Article

(Visited 2 times, 1 visits today)